Piper Sandler analyst Matt O’Brien lowered the firm’s price target on Sight Sciences (SGHT) to $5.50 from $6 and keeps a Neutral rating on the shares following Q3 results. The firm worries that competitive trialing in the coming quarters could weigh on the name and prefers to stay on the sidelines until it sees sustained evidence of a re-acceleration on the top-line, Piper told investors.
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SGHT:
- Sight Sciences Reports Modest Growth and Optimistic Outlook
- Sight Sciences backs FY24 revenue view, sees operating expenses down 4%-6%
- Sight Sciences reports Q3 EPS (22c), consensus (21c)
- Sight Sciences Reports Revenue Growth and Leadership Change
- Sight Sciences downgraded to Hold from Buy at Lake Street